NRAS and acute myeloid leukemia: Signal transduction genes were mutated in 34% (41/121) of patients; in AML, the most frequently mutated genes within this group were NRAS (16%, 9/58) and FLT3 (14%, 8/58; 6 ITD and 2 TKD).